Suchergebnisse - "Engelhardt, Monika"

PubPharm (20)

1

Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines

enthalten in: Leukemia research | 2024

von Zeissig, M. | Hewett, D. | Mrozik, K. | +7

2

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

3

Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma

enthalten in: Journal of cancer research and clinical oncology | 2022

von Waldschmidt, J. | Fruttiger, S. | Wider, D. | +9

4

Proteasome inhibition : the dawn of novel therapies in multiple myeloma

enthalten in: Haematologica | 2022

von Engelhardt, M. | Waldschmidt, J. | Wäsch, R.

5

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

6

Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma

enthalten in: European journal of haematology | 2021

von Straka, C. | Salwender, H. | Knop, S. | +16

7

Expert review on soft-tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations

enthalten in: British journal of haematology | 2021

von Rosiñol, L. | Beksac, M. | Zamagni, E. | +35

8

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

9

Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials

enthalten in: European journal of haematology | 2019

von Straka, C. | Knop, S. | Vogel, M. | +18

10

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Richardson, P. | Oriol, A. | Beksac, M. | +123

CommentIn: Lancet Oncol. 2019 Jun;20(6):743-744. - PMID 31097404